Publication | Closed Access

Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study

ThrombopoiesisThrombosisVenous ThrombosisAutoimmune DiseaseBlood PlateletChronic Immune ThrombocytopeniaImmunologyHematologyPlatelet AntagonistOral EltrombopagExtension StudyPharmacotherapyImmunotherapyMedicineAnticoagulant